Publications by authors named "Marc Girard"

Claim this Profile
M
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Nathaniel Lizak, Sifat Sharmin, Dana Horáková, Eva Kubala Havrdova, Sara Eichau, Marc Girard

Mult Scler· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Yi Chao Foong, Daniel Merlo, Melissa Gresle, Katherine Buzzard, Dana Horakova, Marc Girard

J Neurol Neurosurg Psychiatry· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Jodie I Roberts, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Serkan Ozakbas, Marc Girard

J Neurol Neurosurg Psychiatry· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral HLA-DRCD141 Classical Monocytes Predict Relapse Risk and Worsening in Multiple Sclerosis.
Karine Thai, Rose-Marie Rebillard, Wendy Klement, Othmane Ayoub, Olivier Tastet, Marc Girard

Neurol Neuroimmunol Neuroinflamm· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Persistent progression independent of relapse activity in multiple sclerosis.
Chao Zhu, Zhen Zhou, Tomas Kalincik, Izanne Roos, Katherine Buzzard, Marc Girard

Brain Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy-Related Disease Outcomes in Women With Moderate to Severe Multiple Sclerosis Disability.
Jessica Shipley, Heidi N Beadnall, Paul G Sanfilippo, Wei Zhen Yeh, Dana Horakova, Marc Girard

JAMA Netw Open· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024).
Vilija G Jokubaitis, Raed Alroughani, Ayse Altintas, Sara Eichau, Stella Hughes, Marc Girard

Mult Scler· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Serkan Ozakbas, Rana Karabudak, Marc Girard

JAMA Neurol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data Network.
Johannes Lorscheider, Alessio Signori, Suvitha Subramaniam, Pascal Benkert, Sandra Vukusic, Marc Girard

J Neurol Neurosurg Psychiatry· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Jannis Müller, Sifat Sharmin, Johannes Lorscheider, Dana Horakova, Eva Kubala Havrdova, Marc Girard

CNS Drugs· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Simona Toscano, Tim Spelman, Serkan Ozakbas, Raed Alroughani, Clara G Chisari, Marc Girard

Neurotherapeutics· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Wei Z Yeh, Anneke Van Der Walt, Olga G Skibina, Tomas Kalincik, Raed Alroughani, Marc Girard

Neurol Neuroimmunol Neuroinflamm· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Anoushka P Lal, Yi Chao Foong, Paul G Sanfilippo, Tim Spelman, Louise Rath, Marc Girard

J Neurol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
Edward De Brouwer, Thijs Becker, Lorin Werthen-Brabants, Pieter Dewulf, Dimitrios Iliadis, Marc Girard

PLOS Digit Health· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term clinical outcomes in patients with multiple sclerosis who are initiating disease-modifying therapy with natalizumab compared with BRACETD first-line therapies.
Helmut Butzkueven, Tomas Kalincik, Francesco Patti, Mark Slee, Bianca Weinstock-Guttman, Marc Girard

Ther Adv Neurol Disord· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Ying Li, Alice Saul, Bruce Taylor, Anne-Louise Ponsonby, Steve Simpson-Yap, Marc Girard

J Neurol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gaining Biological Insights through Supervised Data Visualization.
Jake S Rhodes, Adrien Aumon, Sacha Morin, Marc Girard, Catherine Larochelle

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of secondary progressive multiple sclerosis after early worsening of disability.
Winston Dzau, Sifat Sharmin, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Marc Girard

J Neurol Neurosurg Psychiatry· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Tim Spelman, Melinda Magyari, Helmut Butzkueven, Anneke Van Der Walt, Sandra Vukusic, Marc Girard

Front Neurol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Sifat Sharmin, Izanne Roos, Steve Simpson-Yap, Charles Malpas, Marina M Sánchez, Marc Girard

Brain· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disability accrual in primary and secondary progressive multiple sclerosis.
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B Malpas, Ibrahima Diouf, Marc Girard

J Neurol Neurosurg Psychiatry· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course, imaging, and pathological features of 45 adult and pediatric cases of myelin oligodendrocyte glycoprotein antibody-associated disease.
Hayet Boudjani, Giulia Fadda, Gabrielle Dufort, Jack Antel, Paul Giacomini, Marc Girard

Mult Scler Relat Disord· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Marc Girard

JAMA Neurol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Cyrus Daruwalla, Vahid Shaygannejad, Serkan Ozakbas, Eva Kubala Havrdova, Dana Horakova, Marc Girard

Mult Scler· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative effectiveness in multiple sclerosis: A methodological comparison.
Izanne Roos, Ibrahima Diouf, Sifat Sharmin, Dana Horakova, Eva Kubala Havrdova, Marc Girard

Mult Scler· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis